Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07560865 · ClinicalTrials.gov registry record · Phase 1
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT07560865: Recruiting Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT07560865 is a Phase 1 study that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07560865, a Phase 1 study, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievable. Per this treatment schema, FT536 will be administered once intratumorally
Primary Outcome
To determine the safety and tolerability of inter-cohort dose escalation intratumoral FT536 as outlined by incidence of adverse events (AEs) based on CTCAE v5.0
Interventions
- BIOLOGICAL FT536
- PROCEDURE Biopsy/ Intratumoral Injection/ Gross Tumor Resection
- DIAGNOSTIC_TEST Blood/ Cerebrospinal Fluid/ Tumor Pathology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2026-04-23 |
| Est. Completion | 2029-06-01 |
| Phase | Phase 1 |
What NCT07560865 shows while recruiting
NCT07560865 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 3 interventions - of which FT536 is the first listed.
NCT07560865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07560865 about?
NCT07560865 is a clinical study titled "First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma". This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievable...
What is the current status of trial NCT07560865?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2026-04-23. Estimated completion is 2029-06-01.
What interventions are being tested in trial NCT07560865?
The interventions under investigation include: FT536 (BIOLOGICAL), Biopsy/ Intratumoral Injection/ Gross Tumor Resection (PROCEDURE), Blood/ Cerebrospinal Fluid/ Tumor Pathology (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07560865?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07560865's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI